Loading
DJI136 is an experimental CAR-T cell therapy from Novartis Pharmaceuticals in phase 2 trials for non-small-cell lung cancer, aimed at DLL3.
DJI136 is a CAR-T cell therapy developed by Novartis Pharmaceuticals. Its target is DLL3 (the sponsor names DLL3). The sponsor states: DLL3-targeted chimeric antigen receptor (CAR) T-cell therapy administered by intravenous infusion. ClinicalTrials.gov describes the intervention as: DLL3 targeted CAR-T therapy administered by intravenous (i.v.) infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07564401, plans to enrol 80 participants with primary completion expected 2031-03-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
DLL3-targeted chimeric antigen receptor (CAR) T-cell therapy administered by intravenous infusion. Connects to DLL3.
1.DJI136 slips into a pocket on DLL3.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"DJI136" OR ABSTRACT:"DJI136") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DJI136, not a curated reading list.
Shares DLL3 and the tag pipeline.
Shares DLL3 and the tag pipeline.
Shares Novartis, Non-small-cell lung cancer and the tag pipeline.
Shares Novartis, Non-small-cell lung cancer and the tag pipeline.
Shares DLL3, Non-small-cell lung cancer and the tag pipeline.
Shares Novartis and the tag pipeline.
Shares Novartis and the tag pipeline.
Shares DLL3, Non-small-cell lung cancer and the tag pipeline.